Live from McKesson Accelerate 2025, Dr. Ira Zackon sits down with Dr. Martin Dietrich to discuss the latest in ROS1+ non-small cell lung cancer. They explore the rarity and significance of ROS1 mutations and clinical presentation. The conversation highlights evolving treatment strategies – from first-generation TKIs to next-generation options – plus safety profiles, resistance mechanisms, and NCCN guideline recommendations. Tune in for practical insights on optimizing therapy and improving outcomes for patients with ROS1+ NSCLC.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.
